Cantex Pharmaceuticals, Inc. is clinical stage pharmaceutical company focused on developing and commercializing proprietary pharmaceuticals which treat cancer through their toxic effects on malignant stem cells.

Cantex's pipeline features two products in Phase II clinical development.  CX-02, a proprietary combination of disulfiram + copper, is being studied as a potential treatment for recurrent glioblastoma, with Phase II trial results expected in the second half of 2017. 

CX-01 is being developed for the treatment of acute myeloid leukemia (AML) and other malignant diseases. A randomized Phase IIb trial of CX-01 in newly diagnosed AML, as well as Phase II trials of CX-01 in myelodysplastic syndrome and acute graft versus host disease, are currently enrolling patients.

 

Latest News

Spotlight

Cantex has two products in Phase II clinical development:

CX-02:

  • Highly active against glioblastoma, triple-negative breast cancer, and other malignant stem cells
  • Unique proprietary formulation combining two compounds with well-established safety

CX-01:

  • 160-patient randomized Phase IIb study in newly diagnosed AML now enrolling
  • Additional Phase II trials in myelodysplastic syndrome and acute graft vs. host disease in 2017